Early Post-marketing Study of Eliquis (Apixaban)
NCT02153424 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2016-08-17
Summary
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
Conditions
- Non-valvular Atrial Fibrillation (NVAF)
Interventions
- DRUG
-
Apixaban
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-30
- Primary Completion
- 2015-11-30
- Completion
- 2015-11-30
Countries
- Mexico
Study Locations
More Related Trials
-
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
NCT03463317 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation
NCT01103674 ·Status: TERMINATED ·Phase: NA
-
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure
NCT03088072 ·Status: UNKNOWN ·Phase: PHASE4
-
Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
NCT05093868 ·Status: WITHDRAWN ·Phase: NA
-
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428 ·Status: RECRUITING ·Phase: PHASE2
-
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
NCT04780438 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
AF Substrate Mapping and Guided Ablation
NCT02571218 ·Status: COMPLETED ·Phase: NA
-
Reduction in Arrhythmia Burden With Left Atrial Posterior Wall Ablation for Persistent AF
NCT05195268 ·Status: WITHDRAWN ·Phase: NA
-
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
NCT01505296 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome
NCT06953778 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PeAF-BOX: Feasibility, Safety and Efficacy of PVI + Box Ablation in Persistent Atrial Fibrillation
NCT05045131 ·Status: COMPLETED ·Phase: NA
-
Individualised Mapping in Persistent AF Ablation
NCT05065112 ·Status: UNKNOWN ·Phase: NA
-
Treatment of PAF With the Synaptic System
NCT05905835 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Fib Clinic of the Future Using KardiaPro Platform for Chronic Care of Patients With AF After Ablation Procedure
NCT03557034 ·Status: COMPLETED ·Phase: NA
-
Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study
NCT03481413 ·Status: TERMINATED
-
The Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System
NCT06990048 ·Status: ACTIVE_NOT_RECRUITING
-
Pulsed Field Ablation During Left Atrial Appendage Occlusion: A Randomised Controlled Trial
NCT06334250 ·Status: WITHDRAWN ·Phase: NA
-
CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation
NCT00227344 ·Status: TERMINATED ·Phase: PHASE4
-
NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
NCT07018596 ·Status: RECRUITING ·Phase: NA
-
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
NCT03854149 ·Status: COMPLETED
-
APIXABAN App Study
NCT06903845 ·Status: RECRUITING ·Phase: NA
-
A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
NCT06168942 ·Status: SUSPENDED ·Phase: NA
-
Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation
NCT01185613 ·Status: COMPLETED ·Phase: PHASE2
-
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
NCT00721149 ·Status: TERMINATED ·Phase: PHASE3
-
Atrial Fibrillation Progression Trial
NCT01570361 ·Status: TERMINATED ·Phase: PHASE4